Rocket Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 13 analysts polled by S&P Global, Rocket Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $9.39. The average 1-year stock price forecast is 241.45% higher than the current stock price, while the lowest is $3.00 (+9.09%) and the highest is $16 (+481.82%).

Price Target: $9.39 (+241.45%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$3.00	$9.39	$10	$16
Change	+9.09%	+241.45%	+263.64%	+481.82%

Analyst Ratings

The average analyst rating for Rocket Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	6	6	6	6	5	5
Buy	0	0	0	0	0	0
Hold	6	6	6	6	6	6
Sell	1	1	1	1	1	1
Strong Sell	1	1	1	1	1	1
Total	14	14	14	14	13	13

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jason Zemansky Bank of America Securities	Bank of America Securities	Buy Reiterates $9 → $10	Buy	Reiterates	$9 → $10	+263.64%	Jun 3, 2026
Tara Bancroft TD Cowen	TD Cowen	Hold Maintains n/a	Hold	Maintains	n/a	n/a	May 11, 2026
Geulah Livshits Chardan Capital	Chardan Capital	Buy Reiterates $11	Buy	Reiterates	$11	+300.00%	May 10, 2026
Whitney Ijem Canaccord Genuity	Canaccord Genuity	Buy Maintains $10	Buy	Maintains	$10	+263.64%	May 8, 2026
Patrick Dolezal LifeSci Capital	LifeSci Capital	Buy Reiterates $12	Buy	Reiterates	$12	+336.36%	May 8, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

17.17M

Revenue Next Year

19.80M

from 17.17M

15.32%

from 17.17M

EPS This Year

-0.82

from -1.98

EPS Next Year

-1.13

from -0.82

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-	17.17M
Operating Income	-166.25M	-223.84M	-256.66M	-273.21M	-228.52M	-165.82M
Net Income	-169.07M	-221.86M	-245.60M	-258.75M	-223.12M	-113.61M
EPS	-	-	-	-	-1.98	-0.82
Free Cash Flow	-82.57M	-99.45M	-119.77M	-133.26M	-104.85M	-123.67M
No. Analysts	-	-	-	-	-	12

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	180.9M
Avg	17.2M
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	657.2%
Avg	15.3%
Low	-100.0%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-0.82
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-